FDA Grants Breakthrough Device Designation to TETmedical's NSE-FAST, the First Rapid Blood Test for Acute Ischemic Stroke Diagnosis
核心洞察
The FDA has granted Breakthrough Device Designation to TETmedical's NSE-FAST (搜索), a rapid enzyme-based luminescence assay that measures Neuron Specific Enolase (搜索) activity in blood plasma to aid in diagnosing acute ischemic stroke (搜索).
Approximately 840,000 Americans suffer an acute stroke annually, with 87% being ischemic; stroke is the leading clinical condition associated with serious misdiagnosis-related harms, with an average of 17% of strokes missed.
The designation provides prioritized FDA access and may position NSE-FAST (搜索) for consideration under the FDA-CMS RAPID coverage pathway to reduce time between authorization and Medicare coverage decisions.
TETmedical, Inc. (搜索), a clinical-stage medical diagnostics company, announced on June 22, 2026 that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its NSE-FAST (搜索) (Neuron Specific Enolase (搜索) — Functional Activity Stroke Test), a rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke (搜索). The designation was issued by the FDA's Center for Devices and Radiological Health (CDRH), Division of Immunology and Hematology Devices.
The NSE-FAST (搜索) represents what the company describes as the first rapid blood test designed to aid in the diagnosis of acute ischemic stroke (搜索), addressing what Dr. David Fischell, Co-Founder and Chief Executive Officer of TETmedical, called "one of medicine's most significant unmet diagnostic needs."
The Diagnostic Challenge in Acute Ischemic Stroke (搜索)
Stroke remains one of the leading causes of death and a major cause of long-term disability in the United States. Each year, approximately 840,000 Americans suffer an acute stroke, of which roughly 87 percent are ischemic, resulting from obstruction of blood flow to the brain. An estimated 2.3 million patients present annually to emergency departments with neurological symptoms suggestive of stroke.
While CT scans are highly effective at identifying hemorrhagic strokes, they frequently fail to detect acute ischemic strokes. A published study by Newman-Toker and colleagues reported that stroke is the number one clinical condition associated with serious misdiagnosis-related harms, with an average of 17 percent of strokes missed.
Dr. Fischell underscored this point: "Acute ischemic stroke (搜索) remains the leading missed diagnosis causing serious harm in emergency medicine. We are gratified that the FDA has recognized the potential of the NSE-FAST (搜索) to help address this longstanding challenge."
How NSE-FAST (搜索) Works
NSE-FAST (搜索) is a rapid, enzyme-based luminescence assay that measures the functional enzymatic activity of Neuron Specific Enolase (搜索) (NSE) in a patient's blood plasma. The test is intended for use alongside other available clinical information to aid in the diagnosis of acute ischemic stroke (搜索) in adult patients. The assay utilizes TETmedical's patented Tethered Enzyme Technology (TET) to rapidly measure NSE functional activity as a biomarker for acute ischemic stroke.
According to Dr. Fischell, the test requires only "a single additional small tube of blood collected under IRB approvals with a waiver of patient informed consent," a feature that may facilitate its integration into emergency department workflows.
Regulatory Pathway and the Breakthrough Devices Program
The FDA Breakthrough Devices Program is designed to accelerate the development and review of medical devices that may provide for more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions where no approved alternatives exist. The designation provides TETmedical with prioritized access to FDA experts, enhanced opportunities for interactions with the agency, and the potential to efficiently align with clinical and regulatory requirements throughout the development process.
Additionally, the Breakthrough Device Designation may position NSE-FAST (搜索) for consideration under emerging FDA-CMS initiatives designed to reduce the time between FDA authorization and Medicare coverage decisions. This program, known as the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, requires additional criteria and inclusion is not guaranteed.
TETmedical noted that the Breakthrough Device Designation does not alter the statutory standards for marketing authorization under Section 510(k), 513(f)(2), or 515(c) of the Federal Food, Drug, and Cosmetic Act, and does not guarantee that a device will ultimately receive FDA authorization or clearance for marketing.
Clinical Development Timeline
TETmedical plans to initiate a multi-center pivotal study in the fourth quarter of 2026. Subject to timely initiation of the study, the company anticipates completing patient enrollment in the second half of 2027 and submitting its marketing application to the FDA by the fourth quarter of 2027.
The NSE-FAST (搜索) represents the lead program arising from TETmedical's patented Tethered Enzyme Technology platform, which the company believes may have broader applications for the diagnosis of acute neurological injury and other disease states. The FDA granted the Breakthrough Device Designation on June 15, 2026.